Geode Capital Management
PRQR icon

Geode Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Geode Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Sell
57,997
-26,912
-32% -$44.3K ﹤0.01% 4085
2026
Q1 		$138K Hold
84,909
– – ﹤0.01% 4042
2025
Q4 		$172K Buy
84,909
+36,087
+74% +$84.3K ﹤0.01% 3961
2025
Q3 		$104K Hold
48,822
– – ﹤0.01% 4121
2025
Q2 		$99.6K Hold
48,822
– – ﹤0.01% 4062
2025
Q1 		$64.9K Hold
48,822
– – ﹤0.01% 4142
2024
Q4 		$129K Buy
48,822
+2,151
+5% +$6.83K ﹤0.01% 4030
2024
Q3 		$84.9K Hold
46,671
– – ﹤0.01% 4151
2024
Q2 		$77.5K Hold
46,671
– – ﹤0.01% 4197
2024
Q1 		$106K Hold
46,671
– – ﹤0.01% 4145
2023
Q4 		$92.4K Buy
46,671
+10,378
+29% +$15.9K ﹤0.01% 4209
2023
Q3 		$47.2K Hold
36,293
– – ﹤0.01% 4432
2023
Q2 		$58.8K Hold
36,293
– – ﹤0.01% 4471
2023
Q1 		$77.3K Hold
36,293
– – ﹤0.01% 4420
2022
Q4 		$134K Hold
36,293
– – ﹤0.01% 4286
2022
Q3 		$27K Hold
36,293
– – ﹤0.01% 4866
2022
Q2 		$28K Hold
36,293
– – ﹤0.01% 4878
2022
Q1 		$32K Hold
36,293
– – ﹤0.01% 4893
2021
Q4 		$290K Hold
36,293
– – ﹤0.01% 4305
2021
Q3 		$303K Buy
36,293
+10,888
+43% +$71.1K ﹤0.01% 4265
2021
Q2 		$171K Buy
25,405
+5,873
+30% +$37.9K ﹤0.01% 4393
2021
Q1 		$129K Buy
19,532
+6,148
+46% +$31.4K ﹤0.01% 4240
2020
Q4 		$56K Sell
13,384
-45,161
-77% -$191K ﹤0.01% 4150
2020
Q3 		$280K Buy
58,545
+3,124
+6% +$16.3K ﹤0.01% 3612
2020
Q2 		$336K Buy
55,421
+1,510
+3% +$8.16K ﹤0.01% 3500
2020
Q1 		$295K Buy
53,911
+840
+2% +$6.44K ﹤0.01% 3433
2019
Q4 		$525K Buy
53,071
+23,560
+80% +$184K ﹤0.01% 3480
2019
Q3 		$169K Hold
29,511
– – ﹤0.01% 3834
2019
Q2 		$268K Hold
29,511
– – ﹤0.01% 3700
2019
Q1 		$409K Buy
29,511
+10,318
+54% +$154K ﹤0.01% 3508
2018
Q4 		$302K Buy
19,193
+2,375
+14% +$43.6K ﹤0.01% 3552
2018
Q3 		$325K Buy
16,818
+5,670
+51% +$60.3K ﹤0.01% 3595
2018
Q2 		$81K Buy
+11,148
New +$56.2K ﹤0.01% 3913
2017
Q4 		– Sell
-12,211
Closed -$59K – 4032
2017
Q3 		$59K Sell
12,211
-786
-6% -$4.08K ﹤0.01% 3907
2017
Q2 		$67K Buy
12,997
+1,409
+12% +$7K ﹤0.01% 3908
2017
Q1 		$57K Buy
11,588
+354
+3% +$1.56K ﹤0.01% 3927
2016
Q4 		$55K Buy
11,234
+236
+2% +$1.22K ﹤0.01% 3896
2016
Q3 		$73K Buy
10,998
+59
+0.5% +$325 ﹤0.01% 3870
2016
Q2 		$52K Buy
+10,939
New +$56.3K ﹤0.01% 3917

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Geode Capital Management's PRQR Position: Q2 2026 in Review

Geode Capital Management reduced its ProQR Therapeutics (PRQR) stake by 32% in Q2 2026, selling an estimated $44.3K and leaving 57,997 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #4085.

Geode Capital Management first reported a position in PRQR in Q2 2016 and has held it in 39 quarters since. The position peaked at $525K in Q4 2019. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Geode Capital Management held 57,997 shares of ProQR Therapeutics worth $108K as of Q2 2026.
  • Geode Capital Management sold 26,912 ProQR Therapeutics shares in Q2 2026, an estimated $44.3K.
  • ProQR Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4085 holding.
  • Geode Capital Management first reported a position in ProQR Therapeutics in Q2 2016 and has held it in 39 quarters since.
  • Geode Capital Management's ProQR Therapeutics position peaked at $525K in Q4 2019.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.